Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Name of e	entity		
Atlas Pea	arls and Perfumes Ltd		
ARN			

We (the entity) give ASX the following information.

#### Part 1 - All issues

32 009 220 053

You must complete the relevant sections (attach sheets if there is not enough space).

- <sup>+</sup>Class of \*securities issued or to be issued
- 1. Fully paid ordinary shares.
- 2. Convertible notes.
- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- 1. 2,053,842 fully paid ordinary shares.
- 2. 350,000 convertible notes.

01/08/2012 Appendix 3B Page 1

<sup>+</sup> See chapter 19 for defined terms.

- Principal of 3 terms the +securities (eg, if options, exercise price and expiry date; if partly paid \*securities, amount outstanding and due dates for payment; if the +convertible securities, conversion price and dates for conversion)
- 1. Fully paid ordinary shares.
- 2. Convertible Notes unlisted unsecured convertible notes with the following principal terms:
  - (i) Face value \$1.00 per convertible note.
  - (ii) Maturity date 1 March 2015.
  - (iii)Convertible at the election of the holder during prescribed 10 business day "windows" prior to the first and second anniversary of the date of issue.
  - (iv) Conversion price the lower of \$0.05 and 90% of the average of the daily volume-weighted average sales price of the Company's shares sold on ASX for each trading day on which shares are sold on ASX during the 10 trading days prior to the conversion date.
  - (v) Interest 6% per annum payable half yearly in arrears with the first interest payment date being 1 September 2013.
  - (vi) Redemption at the election of the Company at any time before the maturity date, otherwise on the maturity date.

Appendix 3B Page 2 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Do the \*securities rank equally in all respects from the date of allotment with an existing \*class of quoted \*securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 5 Issue price or consideration

- 1. Yes fully paid ordinary shares.
- 2. No but the shares issued on conversion of the convertible notes will rank equally with fully paid ordinary shares from the date of allotment.

- 1. Fully paid ordinary shares 1,220,509 issued at \$0.05 per share and 833,333 issued at \$0.06 per share.
- 2. Convertible notes \$1.00 per note.

01/08/2012 Appendix 3B Page 3

<sup>+</sup> See chapter 19 for defined terms.

- 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)
- 1. Issue of (i) 103,709 fully paid ordinary shares on exercise of 103,709 unlisted options exercisable at \$0.05 each, on or before 29 January 2014; (ii) 833,333 fully paid ordinary shares as announced to ASX on 25 October 2012 and approved by shareholders in the General Meeting of Shareholders held on 4 December 2012 and (iii) 1,116,800 fully paid ordinary shares as placement of the shortfall from the Company's non-renounceable entitlements offer that closed on 18 January 2013.
- 2. Issue of 350,000 convertible notes as announced to ASX on 25 October 2012 and approved by shareholders in the General Meeting of Shareholders held on 4 December 2012.

The funds raised from all issues will be used to:

- (a) support existing current assets;
- (b) reduce existing debt in the Essential Oils of Tasmania business;
- (c) fund research and development initiatives;
- (d) fund increased production of strategic pearl by-product and perfume ingredients and commercialisation of new consumer products through World Senses Pty Ltd;
- (e) fund expansion of the existing pearl auction strategy; and
- (f) strengthen the balance sheet for general working capital purposes.

6a	Is the	entit	y an †eligil	ole entity
	that	has	obtained	security
	holde	r appr	oval under i	rule 7.1A?

If Yes, complete sections 6b – 6h in relation to the \*securities the subject of this Appendix 3B, and comply with section 6i

6b The date the security holder resolution under rule 7.1A was passed

N/A

Appendix 3B Page 4 o1/08/2012

No

<sup>+</sup> See chapter 19 for defined terms.

6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of securities issued under an exception in rule 7.2	N/A
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	1 March 2013

o1/08/2012 Appendix 3B Page 5

<sup>+</sup> See chapter 19 for defined terms.

8 Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable)

Number	<sup>+</sup> Class
282,762,983	Fully paid ordinary shares (ASX code: ATP)

Number and +class of all +securities not quoted on ASX (including the securities in section 2 if applicable)

Number	+Class
30,137,026	Options exercisable
	at \$0.05 each, on or
	before 29 January
	2014.
950,000	Convertible notes

10 trust, distribution policy) on the increased capital (interests)

Dividend policy (in the case of a Dividends are paid as authorised by Directors.

## Part 2 - Bonus issue or pro rata issue

11	Is security holder approval N/A required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
	<u></u>	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	

Appendix 3B Page 6 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to	
	the broker to the issue	
2.4		
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on	
24	Amount of any handling fee payable to brokers who lodge	
·	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on	
·	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders  If the issue is contingent on *security holders' approval, the	
·	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders  If the issue is contingent on *security holders' approval, the	
25	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders  If the issue is contingent on *security holders' approval, the date of the meeting  Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
25	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders  If the issue is contingent on *security holders' approval, the date of the meeting  Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled  If the entity has issued options,	
25	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders  If the issue is contingent on *security holders' approval, the date of the meeting  Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled  If the entity has issued options, and the terms entitle option holders to participate on	
25	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders  If the issue is contingent on *security holders' approval, the date of the meeting  Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled  If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which	
25	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders  If the issue is contingent on *security holders' approval, the date of the meeting  Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled  If the entity has issued options, and the terms entitle option holders to participate on	
25	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders  If the issue is contingent on *security holders' approval, the date of the meeting  Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled  If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
<sup>2</sup> 5	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders  If the issue is contingent on *security holders' approval, the date of the meeting  Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled  If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option	

oı/o8/2012 Appendix 3B Page 7

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B New issue announcement

29	Date rights trading will end (if applicable)	
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	
31	How do *security holders sell part of their entitlements through a broker and accept for the balance?	
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	
33	<sup>+</sup> Despatch date	
Part	3 - Quotation of securitie	es.
	ed only complete this section if you are a	
34	Type of securities (tick one)	
(a)	Securities described in Part	1 d ordinary shares should be quoted.
(b)	All other securities	rorumary shares should be quoted.
(6)	Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities	
Entiti	es that have ticked box 34(a)	
Addit	ional securities forming a nev	v class of securities
naun	ional securities forming a nev	veluss of securities
Tick to docum	indicate you are providing the informa	tion or
35	1 1	v securities, the names of the 20 largest holders of the the number and percentage of additional *securities
36	_	y securities, a distribution schedule of the additional number of holders in the categories

Appendix 3B Page 8 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

	1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over		
37	A copy of any trust deed for t	the additional <sup>+</sup> securities	
Entiti	es that have ticked box 34(b)		
38	Number of securities for which <sup>+</sup> quotation is sought	N/A	
39	Class of *securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?  If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another security, clearly identify that other security)		
		Number	+Class

o1/08/2012 Appendix 3B Page 9

<sup>+</sup> See chapter 19 for defined terms.

Number and \*class of all \*securities quoted on ASX (including the securities in clause 38)

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 
  +securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Appendix 3B Page 10 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Sign here: Date: 7 March 2013

(Director/Company secretary)

PHurte.

Print name: SUSAN HUNTER

== == == ==

01/08/2012 Appendix 3B Page 11

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B - Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for †eligible entities

Introduced 01/08/12

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital  Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
		Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue
<ul> <li>Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid ordinary securities that became fully paid in that 12 month period</li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> <li>Subtract the number of fully paid ordinary securities cancelled during that 12 month period</li> </ul>	N/A	
"A"	N/A	

Appendix 3B Page 12 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	N/A
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule
Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:	N/A
Under an exception in rule 7.2	
Under rule 7.1A	
With security holder approval under rule 7.1 or rule 7.4	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	N/A
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining
"A" x 0.15	N/A
Note: number must be same as shown in Step 2	
Subtract "C"	N/A
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.15] – "C"	N/A
	[Note: this is the remaining placement capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

oı/o8/2012 Appendix 3B Page 13

## Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	N/A	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	N/A	
7.1A that has already been used  Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	N/A	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with</li> </ul>		
<ul> <li>in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		

Appendix 3B Page 14 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	N/A
Note: number must be same as shown in Step 2	
Subtract "E"	N/A
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E"	N/A
	Note: this is the remaining placement capacity under rule 7.1A

oı/o8/2012 Appendix 3B Page 15

<sup>+</sup> See chapter 19 for defined terms.